The U.S. Food and Drug Administration declined to approve AstraZeneca Plc’s diabetes treatment Farxiga for use as a supplement to insulin in adults with a rare type of the condition.

The United States pays more per capita for prescription drugs than any other country in the world, which is a huge concern for patients and insurance providers.

Novo Nordisk’s diabetes drug Victoza (liraglutide) earned approval from the U.S. FDA for an expanded indication for use in children ages 10 to 17 years who have type 2 diabetes.

Insulin-dependent patients with T2D saw a significant drop in blood sugar levels after wearing Abbott’s continuous glucose monitoring system compared with those who use routine fingerstick testing.

The Canadian province of British Columbia said its public drug plan will switch as many as 20,400 patients from three branded biologic drugs to cheap near-copies called biosimilars.

Indianapolis-based Eli Lilly announced that the company’s Lispro Injection, an authorized generic version of the life-saving insulin Humalog, is available at pharmacies at a 50 percent lower list price.

Eli Lilly reported lower-than-expected first-quarter 2019 sales for the company’s top-selling diabetes drug Trulicity, due in part to patient affordability programs.

Sanofi SA will cut the cost of the company’s insulin products to $99 per month for uninsured patients and others who pay cash for the medicine in the United States, as the French drugmaker contends with intense criticism over the high price of the life-sustaining diabetes medication.

Health insurer Cigna Corp. launched a program aimed at ensuring some diabetes patients pay no more than $25 for a 30-day supply of insulin in the wake of heightened public scrutiny over soaring prices of the life-saving drug.

Novo Nordisk submitted the company’s oral semaglutide drug, a pill that management hopes will transform the diabetes market, for approval in the United States.